BMRN
Biomarin Pharmaceutical Inc
61.40$
-1.4%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| -58.3% | -115.0% | -68.1% | 391.7% | 461.2% | 514.1% | 21.2% | 10.2% | 10.4% | 15.1% | 17.7% | 20.3% | 18.7% | 19.0% | 18.3% | 16.1% | 16.3% | 17.1% | 18.8% | 18.4% | 21.1% | 21.1% | 28.2% | 25.5% | 24.0% | 22.0% | 20.3% | 22.9% | |
| 158.3% | 246.6% | 195.0% | 100.0% | 100.0% | 100.0% | 78.8% | 89.8% | 89.6% | 84.9% | 82.3% | 79.7% | 81.3% | 81.0% | 81.7% | 83.9% | 83.7% | 82.9% | 81.2% | 81.6% | 78.9% | 78.9% | 71.8% | 74.5% | 76.0% | 78.0% | 79.7% | 77.1% | |
| 875.0% | 513.3% | 368.5% | 387.1% | 391.2% | 453.0% | 267.1% | 219.7% | 79.2% | 64.6% | 31.5% | 35.5% | 39.2% | 48.6% | 60.4% | 64.7% | 61.6% | 71.3% | 59.3% | 46.5% | 46.7% | 42.0% | 33.8% | 34.1% | 31.0% | 30.9% | 26.2% | 28.6% | |
| 291.7% | 128.4% | 90.7% | 57.4% | 126.0% | 119.0% | 201.7% | 161.9% | 58.2% | 63.8% | 35.9% | 38.3% | 40.3% | 39.7% | 39.6% | 42.9% | 40.3% | 45.2% | 42.7% | 42.2% | 18.8% | 17.5% | 18.0% | 19.2% | 17.8% | 16.7% | 18.7% | 35.8% | |
| 1,233.3% | 701.7% | 535.3% | 606.7% | 666.5% | 726.5% | 1,041.0% | 339.9% | 118.9% | 132.0% | 68.9% | 74.6% | 81.2% | 88.6% | 103.7% | 112.3% | 96.1% | 95.4% | 153.2% | 82.7% | 87.1% | 84.8% | 74.2% | 79.0% | 68.3% | 70.3% | 62.7% | 60.6% | |
| -1,075.0% | -486.8% | -367.3% | -506.7% | -566.5% | -626.5% | -962.2% | -250.2% | -29.3% | -47.1% | 13.4% | 5.1% | 0.1% | -7.7% | -22.0% | -28.4% | -12.4% | -12.4% | -71.9% | -1.1% | -8.3% | -5.9% | -2.3% | -4.5% | 7.7% | 7.7% | 17.0% | 16.6% | |
| 0.0% | 0.0% | 0.1% | 0.0% | 3.9% | 25.9% | 56.6% | 46.4% | 19.9% | 11.7% | 5.5% | 4.3% | 2.7% | 1.9% | 1.5% | 1.9% | 4.9% | 4.3% | 3.5% | 3.3% | 2.9% | 1.4% | 1.6% | 0.8% | 0.8% | 0.7% | 0.4% | 0.3% | |
| -1,025.0% | -550.4% | -415.2% | -606.3% | -556.5% | -626.4% | -1,005.5% | -289.3% | -33.9% | -12.4% | 11.3% | 0.2% | -5.7% | -9.9% | -23.6% | -32.2% | -16.7% | -17.4% | -74.4% | -2.7% | -9.6% | -5.6% | -2.6% | -4.1% | 7.1% | 7.8% | 19.0% | 15.0% | |
| -50.0% | 10.8% | 44.9% | 170.7% | 70.7% | 0.0% | 196.1% | 85.3% | 27.5% | 0.6% | 0.9% | 0.3% | -60.4% | 2.3% | -0.8% | 0.0% | 1.2% | 1.9% | -18.0% | 6.2% | -4.4% | -4.2% | -48.5% | -0.6% | 0.4% | 0.9% | 4.0% | 4.1% | |
| -1,025.0% | -529.7% | -384.6% | -577.9% | -556.5% | -626.4% | -1,005.5% | -289.3% | -33.9% | -13.0% | 10.4% | -0.2% | 54.7% | -12.2% | -22.8% | -32.2% | -17.9% | -19.3% | -56.4% | -8.9% | -5.2% | -1.4% | 45.9% | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% | |
| -1,008.3% | -384.6% | -308.2% | -347.3% | -424.7% | -548.4% | -722.2% | -212.2% | -17.7% | -43.5% | 22.7% | 11.0% | 4.5% | 0.0% | -13.4% | -23.9% | -6.1% | -8.2% | -62.5% | 6.9% | -0.2% | 1.9% | 4.5% | 2.6% | 12.7% | 12.7% | 22.8% | 17.8% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.